hematologic disease: A disease involving the hematopoietic system.
Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
DOID EFO Endpoint Browser PheWeb
D3_OTHDISLYMPHORETANDRETICULOHIST
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
118 |
4. Check minimum number of eventsNone |
118 |
5. Include endpoints |
118 |
6. Filter based on genotype QC (FinnGen only) |
118 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D70-D77
- Name in latin
- Aliqui morbi textus lymphoreticularis et systematis reticulohistiocytici
Similar endpoints
↥List of similar endpoints to
Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
based on the number of shared cases.
Similar with more cases:
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 896 | 420 | 473 |
| Only index persons | 719 | 332 | 387 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 34.32 | 35.37 | 33.34 |
| Only index persons | 41.02 | 42.89 | 39.42 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 118 | 55 | 63 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 52.10 | 52.89 | 51.41 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 104
- Matched controls
- 1041
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D76.1
ICD-10 Finland
Haemophagocytic lymphohistiocytosis
+∞
46.4
41
*
D76.3
ICD-10 Finland
Other histiocytosis syndromes
+∞
42.7
38
*
D76.00
ICD-10 Finland
Eosinophilic granuloma
+∞
31.9
29
*
D76.01
ICD-10 Finland
Histiocytosis X (chronic)
+∞
22.7
21
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
14.5
21.9
39
41
XW000
NOMESCO Finland
Bone marrow biopsy
31.3
21.4
28
12
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
26.8
20.4
28
14
H02AB09
ATC
hydrocortisone; systemic
32.7
14.9
19
7
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
7.1
14.6
40
84
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
86.5
14.0
15
*
JN4BD
NOMESCO Finland
Extensive body CT
8.9
13.1
29
43
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.9
13.1
70
307
R50.9
ICD-10 Finland
Fever, unspecified
6.3
12.8
38
87
WW500
NOMESCO Finland
Blood transfusion
19.0
12.7
19
12
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.8
11.5
36
87
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
67.1
10.9
12
*
JN4AD
NOMESCO Finland
Body CT examination
11.5
10.9
20
21
N17.9
ICD-10 Finland
Acute renal failure, unspecified
14.2
10.8
18
15
H02AB06
ATC
prednisolone; systemic
4.1
10.6
67
318
H02AB02
ATC
dexamethasone; systemic
8.6
10.5
23
33
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
10.8
10.0
19
21
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
13.3
10.0
17
15
D64.9
ICD-10 Finland
Anaemia, unspecified
7.9
10.0
23
36
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
11.7
9.4
17
17
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.1
9.4
46
169
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.2
9.1
22
37
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.5
9.0
24
46
ZX120
NOMESCO Finland
Intravenous
7.1
8.9
22
38
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.0
8.8
25
52
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
6.9
8.8
22
39
A41.9
ICD-10 Finland
Sepsis, unspecified
14.5
8.7
14
11
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
97.6
8.5
9
*
D76.0
ICD-10 Finland
Langerhans' cell histiocytosis, not elsewhere classified
+∞
8.4
8
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
8.4
8
*
D76.2
ICD-10 Finland
Haemophagocytic syndrome, infection-associated
+∞
8.4
8
*
L03AA02
ATC
filgrastim; parenteral
36.5
8.2
10
*
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
13.3
7.8
13
11
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.3
7.8
14
14
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
6.8
7.7
19
33
TPX10
NOMESCO Finland
Implantation of vascular injection port
14.9
7.6
12
9
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.6
7.3
26
70
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
9.3
7.1
14
17
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
18.2
6.9
10
6
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.7
6.8
19
39
GD1AD
NOMESCO Finland
Thorax CT examination
9.7
6.8
13
15
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.7
6.8
13
15
M04AA01
ATC
allopurinol; systemic
4.8
6.6
22
55
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
9.1
6.6
13
16
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
15.6
6.5
10
7
JN6AD
NOMESCO Finland
CT of torso and neck
74.2
6.5
7
*
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
28.6
6.3
8
*
ZX108
NOMESCO Finland
Inhalation
28.6
6.3
8
*
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
28.6
6.3
8
*
102
Kela drug reimbursment
Diabetes insipidus
+∞
6.3
6
*
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
40
34
17.29
41.68
2.6
1.9
1.6
1.6
g/l
0.07
30
27
42
6
107.04
40.14
7.7
1.8
3986.2
566.5
u/ml
—
42
6
26
10
33.07
38.30
3.9
4.5
—
—
—
0
0
30
19
20.83
36.16
2.3
2.9
—
—
—
0
0
31
28
14.66
30.65
2.6
2.7
—
—
—
0
0
21
10
25.33
28.30
3.5
3.5
476.5
621.4
e6/l
—
10
5
27
24
14.29
26.77
3.8
1.8
—
—
—
0
0
23
16
17.61
26.09
1.5
1.4
—
—
—
0
0
26
23
14.22
25.81
3.2
1.8
—
—
—
0
0
25
22
14.15
24.85
1.5
1.4
—
—
—
0
0
23
19
14.79
23.67
4.0
1.8
—
—
—
0
0
21
15
16.81
23.39
1.5
1.3
—
—
—
0
0
23
20
14.04
22.95
1.6
2.4
—
—
—
0
0
23
20
14.04
22.95
1.3
1.9
—
—
—
0
0
54
135
6.53
22.56
11.1
8.3
1.1
1.2
mmol/l
0.44
54
124
21
17
14.81
21.79
1.5
1.3
—
—
—
0
0
19
14
15.98
20.71
2.2
1.7
—
—
—
0
0
22
23
11.53
19.40
1.8
1.5
—
—
—
0
0
22
7
38.11
17.77
2.2
1.4
—
—
—
0
0
17
14
14.02
17.29
4.2
1.6
—
—
—
0
0
16
0
+∞
17.08
2.2
0.0
—
—
—
0
0
52
157
5.13
16.86
12.9
6.1
0.8
0.8
mmol/l
0.09
52
146
19
20
11.13
16.56
1.6
2.4
294.9
137.5
u/ml
—
10
11
21
27
9.25
15.82
2.5
1.1
6.6
7.6
g/l
1.34
15
21
21
27
9.25
15.82
2.5
1.1
—
—
—
0
0
21
27
9.25
15.82
2.5
1.1
3.5
3.6
g/l
0.08
15
21
16
14
13.06
15.65
1.5
1.1
—
—
—
0
0
15
12
14.17
15.44
4.7
1.8
—
—
—
0
0
22
31
8.49
15.40
1.8
1.5
—
—
—
0
0
48
148
4.78
14.92
7.1
2.6
29.7
30.3
s
0.29
48
143
20
26
9.06
14.90
2.8
1.7
—
—
—
0
0
15
13
13.07
14.71
2.3
1.8
—
—
—
0
0
91
463
5.22
14.33
20.0
7.7
1.2
1.2
mmol/l
0.21
71
396
24
41
7.09
14.16
8.8
3.9
89.8
92.9
%
0.20
24
41
27
53
6.31
13.93
3.3
1.3
—
—
—
0
0
17
21
9.29
13.10
2.1
1.2
—
—
—
0
0
44
145
4.24
12.23
4.1
1.6
—
—
—
0
0
97
584
4.71
10.64
37.1
9.8
3.8
4.0
e9/l
0.29
91
504
32
94
4.30
10.20
3.2
2.4
301.8
341.7
nmol/l
0.63
32
84
11
12
10.01
9.12
2.0
1.8
—
—
—
0
0
31
103
3.73
8.21
3.0
1.6
—
—
—
0
0
10
11
9.84
8.20
1.6
2.2
—
—
—
0
0
11
14
8.56
8.13
1.2
1.1
—
—
—
0
0
12
8
16.50
7.90
1.7
1.3
—
—
—
0
0
11
7
17.15
7.38
1.8
1.1
—
—
—
0
0
10
5
21.65
7.26
2.9
1.4
—
—
—
0
0
29
100
3.52
7.21
3.1
1.5
—
—
—
0
0
11
8
14.99
7.04
1.2
1.0
—
—
—
0
0
11
17
7.03
6.90
6.7
4.0
53.0
60.8
%
0.69
11
17
15
32
5.22
6.90
10.2
3.3
212.3
206.7
%
0.08
15
32
72
428
2.75
6.62
11.4
4.1
—
—
—
0
0
11
18
6.64
6.55
1.3
1.3
—
—
—
0
0
29
106
3.30
6.54
17.3
7.0
104.4
103.8
mmol/l
0.35
29
101
17
45
4.25
6.06
5.4
14.4
95.1
93.8
%
0.54
17
45
9
6
16.07
6.00
1.7
1.0
—
—
—
0
0
13
28
5.09
5.89
1.4
1.4
—
—
—
0
0
9
7
13.77
5.68
1.7
1.0
—
—
—
0
0
11
21
5.67
5.64
2.0
1.4
—
—
—
0
0
9
8
12.04
5.39
5.0
1.6
—
—
—
0
0
9
8
12.04
5.39
1.1
1.0
—
—
—
0
0
9
8
12.04
5.39
5.0
1.6
—
—
—
0
0
9
8
12.04
5.39
5.0
1.6
—
—
—
0
0
13
31
4.59
5.24
1.2
1.2
—
—
—
0
0
59
348
2.39
5.12
5.3
3.5
—
—
—
0
0
25
97
3.00
5.04
5.0
13.8
0.5
1.5
mmol/l
0.77
20
81
26
104
2.92
4.97
18.1
6.1
1.4
1.6
mmol/l
0.19
21
79
43
224
2.45
4.87
8.2
2.3
—
—
—
0
0
24
93
2.98
4.84
5.2
14.2
4.6
5.2
kpa
2.38
24
87
24
93
2.98
4.84
5.2
14.3
11.3
12.0
kpa
0.37
24
88
23
87
3.04
4.83
5.3
5.3
1.7
1.5
mmol/l
0.08
18
63
53
305
2.34
4.79
4.0
3.5
2.3
2.4
mmol/l
2.17
53
266
7
5
14.75
4.63
1.3
1.8
—
—
—
0
0
13
36
3.93
4.34
1.8
2.6
18.2
23.5
iu/l
—
8
28
22
87
2.88
4.26
17.3
8.6
24.0
24.6
mmol/l
0.36
22
87
12
34
3.82
3.88
5.3
1.8
—
—
—
0
0
7
8
9.21
3.82
1.1
1.5
—
—
—
0
0
6
5
12.53
3.80
6.0
2.0
—
—
—
0
0
6
5
12.53
3.80
6.0
2.0
—
—
—
0
0
6
5
12.53
3.80
1.5
1.2
—
—
—
0
0
6
5
12.53
3.80
5.8
2.0
—
—
—
0
0
6
5
12.53
3.80
5.8
2.0
—
—
—
0
0
6
5
12.53
3.80
6.0
2.0
—
—
—
0
0
6
5
12.53
3.80
5.8
2.0
—
—
—
0
0
6
5
12.53
3.80
6.0
2.0
—
—
—
0
0
47
279
2.14
3.76
5.4
3.4
0.4
0.3
e6/l
0.15
40
214
8
12
7.06
3.74
1.5
1.2
—
—
—
0
0
8
12
7.06
3.74
1.3
1.1
1.7
1.3
g/l
—
8
12
9
17
5.63
3.58
1.3
1.4
—
—
—
0
0
6
6
10.44
3.53
1.3
1.0
—
—
—
0
0
12
39
3.31
3.19
9.7
3.1
25.1
24.8
mmol/l
0.13
12
39
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
5
10.36
3.00
1.6
1.2
—
—
—
0
0
52
347
1.89
2.84
2.2
1.9
79.4
95.9
pmol/l
2.68
35
184
5
6
8.63
2.77
2.0
3.8
102.6
81.3
%
—
5
6
6
10
6.25
2.73
2.7
1.3
—
—
—
0
0
6
10
6.25
2.73
2.7
1.3
—
—
—
0
0
6
10
6.25
2.73
2.7
1.3
—
—
—
0
0
51
344
1.85
2.66
5.2
3.8
28.4
28.2
ng/l
0.01
42
231
13
50
2.80
2.63
29.3
3.2
117.8
132.4
g/l
1.18
13
50
6
11
5.68
2.57
1.0
1.1
—
—
—
0
0
5
7
7.39
2.57
5.2
5.4
—
—
—
0
0
5
7
7.39
2.57
1.6
1.0
—
—
—
0
0
11
39
3.01
2.55
2.5
1.2
—
—
—
0
0
29
166
1.99
2.44
4.6
3.3
42.0
138.3
ng/l
1.24
24
122
19
92
2.27
2.43
6.8
3.4
—
—
—
0
0
6
12
5.20
2.43
1.0
1.0
—
—
—
0
0
12
48
2.67
2.26
3.0
1.6
—
—
—
0
0
39
253
1.81
2.24
1.8
1.7
2.0
1.3
mmol/l
2.75
33
215
5
10
5.17
2.09
3.0
1.3
—
—
—
0
0
5
10
5.17
2.09
3.0
1.3
—
—
—
0
0
5
10
5.17
2.09
3.0
1.3
—
—
—
0
0
7
20
3.65
2.09
2.9
1.3
—
—
—
0
0
38
250
1.77
2.07
6.6
3.9
0.0
0.0
estimate
0.49
21
94
61
463
1.66
1.94
7.9
5.0
0.0
0.0
estimate
0.00
22
94
29
179
1.82
1.94
1.4
1.2
48.3
25.7
iu/ml
0.45
12
58
61
464
1.65
1.92
6.0
3.6
0.0
0.0
estimate
0.00
22
97
61
468
1.63
1.83
6.0
3.6
0.0
0.0
estimate
0.00
22
92
6
18
3.45
1.77
2.0
1.6
—
—
—
0
0
6
18
3.45
1.77
2.0
1.6
—
—
—
0
0
13
62
2.23
1.73
3.3
2.9
92.8
105.1
ng/l
0.11
13
56
14
69
2.17
1.73
25.3
7.6
23.6
23.7
mmol/l
0.03
14
64
8
32
2.61
1.63
3.4
1.6
—
—
—
0
0
49
365
1.59
1.61
6.2
3.6
—
—
—
0
0
5
15
3.43
1.54
5.0
3.5
—
—
—
0
0
9
37
2.55
1.51
1.3
1.2
—
—
—
0
0
9
39
2.41
1.46
20.0
3.7
39.6
52.5
%
—
9
39
108
987
2.11
1.46
52.1
12.9
29.5
23.3
mg/l
1.28
98
744
5
16
3.21
1.45
1.0
1.1
—
—
—
0
0
24
155
1.69
1.37
5.1
3.3
1.1
1.8
e6/l
0.45
15
93
12
66
1.91
1.14
1.6
2.8
59.5
68.2
ml/min/173m2
—
6
29
24
164
1.58
1.10
4.6
3.2
1.2
0.9
e6/l
0.30
15
102
98
890
1.60
1.09
5.2
4.4
1.9
1.9
mu/l
0.14
98
808
23
161
1.53
0.96
1.3
1.3
62.9
5.2
u/ml
—
6
61
16
103
1.64
0.93
2.4
5.2
29.8
48.6
ug/l
—
10
86
15
96
1.64
0.89
1.8
2.5
29.2
29.5
u/l
0.03
15
81
106
994
1.65
0.85
47.2
15.3
139.2
139.8
mmol/l
2.07
106
974
10
58
1.79
0.82
7.9
14.7
22.9
25.1
mmol/l
—
10
53
106
1000
1.59
0.75
50.0
15.3
4.0
4.0
mmol/l
0.18
106
974
9
57
1.63
0.73
3.9
3.6
0.3
0.1
e6/l
—
9
57
97
910
1.37
0.60
5.8
4.4
5.9
5.9
mmol/l
0.02
89
836
27
218
1.31
0.53
1.4
1.7
—
—
—
0
0
6
92
0.63
0.44
1.5
1.6
—
—
—
0
0
21
253
0.79
0.38
3.5
4.1
22.2
23.1
%
—
10
102
10
73
1.40
0.36
2.1
2.5
6.5
5.3
ug/l
—
10
67
12
92
1.34
0.33
14.0
7.3
—
—
—
0
0
108
1049
1.35
0.33
36.7
9.7
40.2
27.3
u/l
1.93
108
1017
84
881
0.84
0.32
6.0
5.5
39.4
39.9
mmol/mol
0.13
76
817
92
880
1.21
0.31
40.8
12.1
83.1
84.3
ml/min/173m2
0.20
85
709
92
955
0.83
0.29
5.3
4.8
2.5
2.7
mmol/l
1.30
85
883
16
131
1.26
0.29
1.5
2.2
1.6
1.4
%
0.30
11
120
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
7.0
—
0
8
11
131
0.82
0.18
3.7
2.1
—
—
—
0
0
110
1111
0.85
0.17
68.0
19.3
123.0
137.6
g/l
9.79
110
1100
13
111
1.19
0.16
28.2
21.1
1.2
1.3
inr
—
5
14
91
934
0.89
0.16
5.0
4.4
1.2
1.4
mmol/l
3.51
85
862
92
939
0.91
0.11
5.0
4.4
4.3
4.6
mmol/l
1.50
86
874
12
107
1.14
0.09
4.0
4.6
25.4
32.0
%
1.66
12
69
12
109
1.11
0.06
1.8
1.3
—
—
—
0
0
25
263
0.94
0.06
1.4
1.5
0.7
1.3
u/ml
—
5
61
71
698
1.04
0.04
3.6
3.1
—
—
—
0
0
11
117
0.93
0.02
3.7
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
6.2
—
—
—
0
0
0
5
0.00
0.00
0.0
6.2
—
—
—
0
0
0
5
0.00
0.00
0.0
6.0
—
224.6
—
0
5
5
52
0.96
0.00
1.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
17.7
—
0
8
0
8
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
5.3
—
61.6
—
0
7
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_OTHDISLYMPHORETANDRETICULOHIST and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_OTHDISLYMPHORETANDRETICULOHIST | 4.294 [2.6, 7.1] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.683 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 345 females with D3_OTHDISLYMPHORETANDRETICULOHIST died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_OTHDISLYMPHORETANDRETICULOHIST | 3.517 [2.18, 5.68] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.029 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 367 males with D3_OTHDISLYMPHORETANDRETICULOHIST died.
Mortality risk
Mortality risk for people of age
years, who have D3_OTHDISLYMPHORETANDRETICULOHIST.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.342% | 0.823% |
| 5 | 2.472% | 4.244% |
| 10 | 5.771% | 10.339% |
| 15 | 11.403% | 19.136% |
| 20 | 20.89% | 30.915% |
Relationships between endpoints
↥Index endpoint: D3_OTHDISLYMPHORETANDRETICULOHIST – Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data